# Paperwork Reduction Act; Notice of Intent To Collect; Comment Request
**AGENCY:**
Office of National Drug Control Policy (ONDCP).
**ACTION:**
ONDCP provides opportunity for public comment concerning the collection of information gathered for the purpose of developing and tracking anti-drug advertising for the National Youth Anti-Drug Media Campaign.
**SUMMARY:**
This action proposes the renewal of three existing data collection instruments used in the production of ONDCP's National Youth Anti-Drug Media Campaign advertising and Media Campaign tracking.
**SUPPLEMENTARY INFORMATION:**
**I. Purpose**
The National Youth Anti-Drug Media Campaign is in the process of renewing three data collection instruments. These data collection instruments—pre-production qualitative (or “focus group”) testing of creative advertising concepts (OMB 3201-0011), pre-broadcast quantitative (or “copy”) testing of developed advertising (OMB 3201-0006) and a tracking study to measure advertising effectiveness (OMB 3201-0010)—are critical to the continuity and improvement of the Media Campaign and are key contributors to the downturn in drug abuse.
*Type of Collections:* OMB 3201-0011—Qualitative Research—Focus groups; OMB 3201-0006—Copytesting—15-minute mall intercept interviews; OMB 3201-0010—Tracking Study—15-minute mall intercept interviews.
*Title of Collection:* See above.
*Frequency:* OMB 3201-0011—Qualitative Research—Quarterly; OMB 3201-0006—Copytesting—Quarterly; OMB 3201-0010—Tracking Study—Weekly.
*Affected Public:* Teenagers and adult influencers of teenagers.
*Estimated Burden:* OMB 3201-0011—Qualitative Research—$11,600; OMB 3201-0006—Copytesting—$16,500; OMB 3201-0010—Tracking Study—$21,000.
**II. Special Issues for Comment**
ONDCP especially invites comments on: (a) Ways to enhance information quality, utility, and clarity of the collection instruments; and (b) ways to ease the burden on respondents, including the use of automated collection techniques or other forms of information technology.
*Comments:* Address comments within 60 days to Mark Krawczyk, Executive Office of the President, Office of National Drug Control Policy, Washington, DC 20503; by e-mail at *[email protected]* ; or, by fax at (202) 395-0858. For further information, contact Mr. Krawczyk at (202) 395-6720.
Signed in Washington, DC, on November 3, 2008.
Daniel R. Petersen,
Assistant General Counsel.